

IMIQUIMOD- imiquimod cream

Padagis Israel Pharmaceuticals Ltd

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use IMIQUIMOD CREAM safely and effectively. See full prescribing information for IMIQUIMOD CREAM.

IMIQUIMOD cream, for topical use

Initial U.S. Approval: 1997

RECENT MAJOR CHANGES

Warnings and Precautions, Local Hypopigmentation Reactions (5.2)

09/2024

INDICATIONS AND USAGE

Imiquimod Cream is indicated for the topical treatment of:

- Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults. (1.1)
- Biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults with a maximum tumor diameter of 2.0 cm on trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. (1.2)
- External genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older. (1.3)

DOSAGE AND ADMINISTRATION

- For topical use only; not for oral, ophthalmic, intra-anal or intravaginal use. (2.1)
- **AK:** Apply once daily before bedtime 2 times per week for a full 16 weeks to a contiguous area of approximately 25 cm² on the face or scalp. Apply no more than 1 packet at each application. (2.2)
- **sBCC:** Apply once daily before bedtime 5 times per week for a full 6 weeks to a target tumor with 2 cm maximum diameter on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet). Amount of Imiquimod Cream used based on target tumor diameter. (2.3)
- **EGW:** Apply thin layer once daily before bedtime 3 times per week until total clearance or for a maximum of 16 weeks. (2.4)

DOSAGE FORMS AND STRENGTHS

- Cream: 5% in unit-dose packets. (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

- **Local Skin Reactions:** Intense local inflammatory reactions can occur (e.g., skin weeping, erosion). Dosage interruption may be required. Severe vulvar swelling may occur and lead to urinary retention; interrupt dosing or discontinue for severe vulvar swelling. (5.1)
- **Local Hypopigmentation Reactions:** Localized complete depigmentation has occurred and persisted. Discontinue if hypopigmentation develops. (5.2)
- **Systemic Reactions:** Flu-like systemic signs and symptoms have occurred. Consider dosage interruption for systemic reactions. (5.3)
- **Ultraviolet Light Exposure Risks:** Avoid or minimize exposure to sunlight and sunlamps. Wear sunscreen and protective clothing. (5.4)

ADVERSE REACTIONS

Most common application site or local skin adverse reactions (incidence >28%) are erythema, flaking/scaling/dryness, scabbing/crusting, edema, erosion/ulceration, induration, itching, burning, excoriation, vesicles. Other reported systemic adverse reactions (≥1%): fatigue, fever, and headache. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Padagis® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Actinic Keratosis
- 1.2 Superficial Basal Cell Carcinoma
- 1.3 External Genital Warts

2 DOSAGE AND ADMINISTRATION

- 2.1 Important Dosage and Administration Instructions
- 2.2 Dosage and Administration for Actinic Keratosis
- 2.3 Dosage and Administration for Superficial Basal Cell Carcinoma
- 2.4 Dosage and Administration for External Genital Warts

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Local Skin Reactions
- 5.2 Local Hypopigmentation Reactions
- 5.3 Systemic Reactions
- 5.4 Ultraviolet Light Exposure Risks

6 ADVERSE REACTIONS

- 6.1 Clinical Trials Experience
- 6.2 Postmarketing Experience

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.2 Lactation
- 8.4 Pediatric Use
- 8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics
- 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

- 14.1 Actinic Keratosis
- 14.2 Superficial Basal Cell Carcinoma
- 14.3 External Genital Warts

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Actinic Keratosis

Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults.

1.2 Superficial Basal Cell Carcinoma

Imiquimod Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured.

Establish the histological diagnosis of superficial basal cell carcinoma prior to treatment. The safety and effectiveness of Imiquimod Cream have not been established for other types of basal cell carcinomas (BCC), including nodular and morpheaform (fibrosing or sclerosing) types.

1.3 External Genital Warts

Imiquimod Cream is indicated for the topical treatment of external genital and perianal warts (EGW) in immunocompetent patients 12 years of age and older.

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosage and Administration Instructions

Imiquimod Cream is for topical use only. Imiquimod Cream is not for oral, ophthalmic, or intravaginal use. Instruct patients on proper application technique.

Wash hands before and after applying Imiquimod Cream. Wash the treatment area with mild soap and water and allow the area to dry thoroughly (at least 10 minutes) before applying Imiquimod Cream.

If an Imiquimod Cream dose is missed, apply the next dose at the regularly scheduled time.

Avoid contact with the eyes, lips, nostrils, or inside the anus and vagina.

For patients with AK and sBCC, prescribe no more than 3 boxes (36 packets) of Imiquimod Cream for the entire treatment period. For EGW, one packet of Imiquimod Cream contains sufficient cream to cover a wart area of up to 20 cm².

Discard partially used packets and do not reuse.

2.2 Dosage and Administration for Actinic Keratosis

Apply Imiquimod Cream topically once daily before bedtime 2 times per week for a full 16

weeks to a defined treatment area of AK on the face or scalp (but not both concurrently). A treatment area is defined as one contiguous area of approximately 25 cm² (e.g., 5 cm × 5 cm) on the face (e.g., forehead or one cheek) or on the scalp. Apply Imiquimod Cream to the entire treatment area and rub in until the cream is no longer visible. Apply no more than 1 packet of Imiquimod Cream to the contiguous treatment area at each application. Leave Imiquimod Cream on the skin for approximately 8 hours and then remove with mild soap and water.

For local skin reactions a dosage interruption of several days may be taken if required by the patient's discomfort or severity of the local skin reaction [see *Warnings and Precautions* (5.1)]. Do not extend treatment beyond 16 weeks due to missed doses or rest periods. Assess response to treatment after resolution of local skin reactions.

2.3 Dosage and Administration for Superficial Basal Cell Carcinoma

Apply Imiquimod Cream topically once daily before bedtime 5 times per week for a full 6 weeks to a biopsy-confirmed sBCC. The target tumor should have a maximum diameter of 2 cm and be located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet). The amount of cream needed to cover the target tumor, including 1 cm of skin surrounding the tumor, is presented in Table 1. Rub Imiquimod Cream into the treatment area until the cream is no longer visible. Leave Imiquimod Cream on the skin for approximately 8 hours and then remove with mild soap and water.

Table 1: Amount of Imiquimod Cream to Use for sBCC

Target Tumor Diameter	Size of Cream Droplet to be Used (Diameter)	Approximate Amount of Imiquimod Cream to be Used
0.5 to <1.0 cm	4 mm	10 mg
≥1.0 to <1.5 cm	5 mm	25 mg
≥1.5 to 2.0 cm	7 mm	40 mg

For local skin reactions a dosage interruption of several days may be taken if required by the patient's discomfort or severity of the local skin reaction [see *Warnings and Precautions* (5.1)].

Assess for early clinical clearance after resolution of local skin reactions (e.g., 12 weeks post-treatment). Local skin reactions or other findings (e.g., infection) may require that a patient be seen sooner than the post-treatment assessment for clinical clearance. If there is clinical evidence of persistent tumor at the post-treatment assessment for clinical clearance, consider a biopsy or other alternative intervention. Instruct patients to contact their healthcare provider if any suspicious lesion arises in the treatment area at any time after a determination of clinical clearance [see *Clinical Studies* (14.2)].

2.4 Dosage and Administration for External Genital Warts

Apply a thin layer of Imiquimod Cream topically once daily before bedtime 3 times per week to EGW until there is total clearance of the genital/perianal warts or for a maximum of 16 weeks. Rub in until the cream is no longer visible. Do not occlude the application site. Leave Imiquimod Cream on the skin for 6 to 10 hours and then remove with mild

soap and water.

For local skin reactions, a dosage interruption of several days may be taken if required by the patient's discomfort or severity of the local skin reaction [see *Warnings and Precautions* (5.1)]. Treatment may resume once the reaction subsides. Nonocclusive dressings such as cotton gauze or cotton underwear may be used to manage skin reactions.

Inform uncircumcised patients treating warts under the foreskin to retract the foreskin and clean the area daily.

Imiquimod Cream may weaken condoms and vaginal diaphragms; therefore, concurrent use is not recommended.

3 DOSAGE FORMS AND STRENGTHS

Cream, 5%: a white to off-white cream in unit-dose packets, with each packet containing 250 mg of cream, equivalent to 12.5 mg of imiquimod.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Local Skin Reactions

Local skin reactions including skin weeping or erosion have been reported with Imiquimod Cream and can occur after a few applications [see *Adverse Reactions* (6.1)]. Concomitant use of Imiquimod Cream and any other imiquimod products, in the same treatment area, may increase the risk for and severity of local skin reactions.

Imiquimod Cream has the potential to exacerbate inflammatory conditions of the skin, including chronic graft versus host disease.

Severe local inflammatory reactions of the female external genitalia can lead to severe vulvar swelling and urinary retention.

Avoid sexual (genital, anal, oral) contact while Imiquimod Cream is on the skin.

To reduce the risk of local skin reactions and manage local skin reactions that occur with Imiquimod Cream treatment:

- Avoid concomitant use of Imiquimod Cream with any other imiquimod product in the same treatment area.
- Avoid application of Imiquimod Cream to skin that is not intact (i.e., any area with an abrasion, cut, burn, rash, infection, or other condition that has altered skin integrity).
- An interruption of dosing may be required for local skin reactions [see *Dosage and Administration* (2.2, 2.3, 2.4)]. Interrupt dosing or discontinue Imiquimod Cream for severe vulvar swelling [see *Dosage and Administration* (2.4)].
- If severe local skin reactions occur, instruct patients to remove Imiquimod Cream

by washing the treatment area with mild soap and water.

5.2 Local Hypopigmentation Reactions

Cases of hypopigmentation, including complete depigmentation, were reported during postmarketing use of Imiquimod Cream. In some cases, hypopigmentation and complete depigmentation did not improve or resolve with treatment and persisted for up to 60 months at the time of reporting. Discontinue Imiquimod Cream if hypopigmentation develops.

5.3 Systemic Reactions

Flu-like signs and symptoms have been reported with use of Imiquimod Cream and may accompany, or even precede, local inflammatory reactions [see *Adverse Reactions (6.1)*]. Signs and symptoms may include malaise, fever, nausea, myalgias, and rigors. Concomitant use of Imiquimod Cream and any other imiquimod products may increase the risk for and severity of systemic reactions. Consider an interruption of dosing if systemic reactions occur.

5.4 Ultraviolet Light Exposure Risks

Imiquimod Cream may cause heightened sunburn susceptibility. Avoid or minimize exposure to sunlight (including sunlamps) during use of Imiquimod Cream. Instruct patients to use sunscreen and wear protective clothing (e.g., a hat). Advise patients not to use Imiquimod Cream until fully recovered from a sunburn.

6 ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

- Local Skin Reactions [see *Warnings and Precautions (5.1)*]
- Local Hypopigmentation Reactions [see *Warnings and Precautions (5.2)*]
- Systemic Reactions [see *Warnings and Precautions (5.3)*]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Actinic Keratosis

The data described below reflect exposure to Imiquimod Cream or vehicle in 436 subjects with AK enrolled in two double-blind, vehicle-controlled trials (Studies AK1 and AK2) [see *Clinical Studies (14.1)*]. Subjects applied Imiquimod Cream, 5% or vehicle topically, to a 25 cm² contiguous treatment area on the face or scalp once daily 2 times per week for 16 weeks.

The incidence of selected adverse reactions reported by $\geq 1\%$ of subjects during the trials is presented in Table 2.

Table 2: Selected Adverse Reactions Occurring in $\geq 1\%$ of Imiquimod-Treated Subjects with AK and at a Greater Frequency than Vehicle in Studies AK1 and

AK2

	Imiquimod Cream (n= 215)	Vehicle (n= 221)
Application Site Reaction	71 (33%)	32 (14%)
Upper Respiratory Tract Infection	33 (15%)	27 (12%)
Sinusitis	16 (7%)	14 (6%)
Headache	11 (5%)	7 (3%)
Carcinoma Squamous	8 (4%)	5 (2%)
Diarrhea	6 (3%)	2 (1%)
Eczema	4 (2%)	3 (1%)
Back Pain	3 (1%)	2 (1%)
Fatigue	3 (1%)	2 (1%)
Fibrillation Atrial	3 (1%)	2 (1%)
Infection Viral	3 (1%)	2 (1%)
Dizziness	3 (1%)	1 (<1%)
Vomiting	3 (1%)	1 (<1%)
Urinary Tract Infection	3 (1%)	1 (<1%)
Fever	3 (1%)	0 (0%)
Rigors	3 (1%)	0 (0%)
Alopecia	3 (1%)	0 (0%)

The incidence of application site reactions reported by >1% of subjects during the trials is presented in Table 3.

Table 3: Application Site Reactions Reported by >1% of Imiquimod-Treated Subjects with AK and at a Greater Frequency than Vehicle in Studies AK1 and AK2

	Imiquimod Cream (n= 215)	Vehicle (n= 221)
Itching	44 (20%)	17 (8%)
Burning	13 (6%)	4 (2%)
Bleeding	7 (3%)	1 (<1%)
Stinging	6 (3%)	2 (1%)
Pain	6 (3%)	2 (1%)
Induration	5 (2%)	3 (1%)
Tenderness	4 (2%)	3 (1%)
Irritation	4 (2%)	0 (0%)

Local skin reactions were collected independently of the adverse reaction "application site reaction". The incidence and severity of local skin reactions that occurred during controlled trials are shown in Table 4.

Table 4: Local Skin Reactions in the Treatment Area of Imiquimod-Treated

Subjects with AK as Assessed by the Investigator in Studies AK1 and AK2

	Imiquimod Cream (n= 215)		Vehicle (n= 220)	
	All Grades*	Severe	All Grades*	Severe
Erythema	209 (97%)	38 (18%)	206 (93%)	5 (2%)
Flaking/Scaling/Dryness	199 (93%)	16 (7%)	199 (91%)	7 (3%)
Scabbing/Crusting	169 (79%)	18 (8%)	92 (42%)	4 (2%)
Edema	106 (49%)	0 (0%)	22 (10%)	0 (0%)
Erosion/Ulceration	103 (48%)	5 (2%)	20 (9%)	0 (0%)
Weeping/Exudate	45 (22%)	0 (0%)	3 (1%)	0 (0%)
Vesicles	19 (9%)	0 (0%)	2 (1%)	0 (0%)

*Mild, Moderate, or Severe

The adverse reactions that most frequently resulted in clinical intervention (e.g., rest periods, withdrawal from trial) were local skin and application site reactions. In the trials, 2% (5/215) of subjects discontinued for local skin/application site reactions. Of the 215 subjects treated, 35 subjects (16%) on imiquimod cream and 3 of 220 subjects (1%) on vehicle had at least one rest period. Of the imiquimod-treated subjects, 32 (91%) resumed therapy after a rest period.

In the AK trials, 22 of 678 (3.2%) of imiquimod-treated subjects developed treatment site infections that required a rest period off imiquimod cream and were treated with antibiotics (19 with oral and 3 with topical).

Of the 206 imiquimod-treated subjects with both baseline and 8-week post-treatment scarring assessments, 6 (2.9%) had a greater degree of scarring scores at 8 weeks post-treatment than at baseline.

Superficial Basal Cell Carcinoma

The data described below reflect exposure to imiquimod cream or vehicle in 364 subjects with sBCC enrolled in two double-blind, vehicle-controlled trials (sBCC1 and sBCC2) [see *Clinical Studies (14.2)*]. Subjects applied imiquimod cream, 5% or vehicle topically 5 times per week for 6 weeks.

The incidence of selected adverse reactions reported by $\geq 1\%$ of subjects during the trials is summarized in Table 5.

Table 5: Selected Adverse Reactions Reported by $\geq 1\%$ of Imiquimod-Treated Subjects with sBCC and at a Greater Frequency than Vehicle in Studies sBCC1 and sBCC2

	Imiquimod Cream (n= 185) N %	Vehicle (n= 179) N %
Application Site Reaction	52 (28%)	5 (3%)
Headache	14 (8%)	4 (2%)
Back Pain	7 (4%)	1 (<1%)
Upper Respiratory Tract	6 (3%)	2 (1%)

Infection		
Rhinitis	5 (3%)	1 (<1%)
Lymphadenopathy	5 (3%)	1 (<1%)
Fatigue	4 (2%)	2 (1%)
Sinusitis	4 (2%)	1 (<1%)
Dyspepsia	3 (2%)	2 (1%)
Coughing	3 (2%)	1 (<1%)
Fever	3 (2%)	0 (0%)
Dizziness	2 (1%)	1 (<1%)
Anxiety	2 (1%)	1 (<1%)
Pharyngitis	2 (1%)	1 (<1%)
Chest Pain	2 (1%)	0 (0%)
Nausea	2 (1%)	0 (0%)

The most frequently reported adverse reactions were local skin and application site reactions. The incidence of application site reactions reported by >1% of the subjects during the 6-week treatment period is summarized in Table 6.

Table 6: Application Site Reactions Reported by > 1% of Imiquimod-Treated Subjects with sBCC and at a Greater Frequency than Vehicle in Studies sBCC1 and sBCC2

	Imiquimod Cream (n= 185)	Vehicle (n= 179)
Itching	30 (16%)	1 (1%)
Burning	11 (6%)	2 (1%)
Pain	6 (3%)	0 (0%)
Bleeding	4 (2%)	0 (0%)
Erythema	3 (2%)	0 (0%)
Papule(s)	3 (2%)	0 (0%)
Tenderness	2 (1%)	0 (0%)
Infection	2 (1%)	0 (0%)

Local skin reactions were collected independently of the adverse reaction “application site reaction”. The incidence and severity of local skin reactions that occurred during the controlled trials are shown in Table 7.

Table 7: Local Skin Reactions in the Treatment Area of Imiquimod-Treated Subjects with sBCC as Assessed by the Investigator in Studies sBCC1 and sBCC2

	Imiquimod Cream (n= 184)		Vehicle (n= 178)	
	All Grades*	Severe	All Grades*	Severe
Erythema	184 (100%)	57 (31%)	173 (97%)	4 (2%)
Flaking/Scaling	167 (91%)	7 (4%)	135 (76%)	0 (0%)
Induration	154 (84%)	11 (6%)	94 (53%)	0 (0%)

Scabbing/Crusting	152 (83%)	35 (19%)	61 (34%)	0 (0%)
Edema	143 (78%)	13 (7%)	64 (36%)	0 (0%)
Erosion	122 (66%)	23 (13%)	25 (14%)	0 (0%)
Ulceration	73 (40%)	11 (6%)	6 (3%)	0 (0%)
Vesicles	57 (31%)	3 (2%)	4 (2%)	0 (0%)

*Mild, Moderate, or Severe

The adverse reactions that most frequently resulted in clinical intervention (e.g., rest periods, withdrawal from trial) were local skin and application site reactions; 10% (19/185) of imiquimod-treated subjects received rest periods. The average number of doses not received per imiquimod-treated subject due to rest periods was 7 doses with a range of 2 to 22 doses; 79% of subjects (15/19) resumed therapy after a rest period. Overall, in the clinical trials, 2% (4/185) of imiquimod-treated subjects discontinued for local skin/application site reactions.

In the sBCC trials, 17 of 1266 (1.3%) imiquimod-treated subjects developed treatment site infections that required a rest period and treatment with antibiotics.

External Genital Warts

In controlled clinical trials for EGW, including a double-blind, vehicle-controlled clinical trial in 209 adult subjects with EGW (Study EGW1) [see *Clinical Studies (14.3)*], imiquimod cream, 5% was applied topically to EGW in 109 subjects. Selected adverse reactions in imiquimod-treated subjects are listed below (see Table 8).

Table 8: Selected Adverse Reactions in Imiquimod-Treated Subjects with EGW in Vehicle-Controlled Clinical Trials

	Females		Males	
	Imiquimod Cream (n=117)	Vehicle (n=103)	Imiquimod Cream (n=156)	Vehicle (n=158)
Wart Site				
Itching	38 (32%)	21 (20%)	34 (22%)	16 (10%)
Burning	30 (26%)	12 (12%)	14 (9%)	8 (5%)
Pain	9 (8%)	2 (2%)	3 (2%)	1 (1%)
Soreness	3 (3%)	0 (0%)	0 (0%)	1 (1%)
Fungal Infection	13 (11%)	3 (3%)	3 (2%)	1 (1%)
Systemic Reactions				
Headache	5 (4%)	3 (3%)	8 (5%)	3 (2%)
Influenza-like Symptoms	4 (3%)	2 (2%)	2 (1%)	0 (0%)
Myalgia	1 (1%)	0 (0%)	2 (1%)	1 (1%)

The most frequently reported adverse reactions were local skin and application site reactions.

Overall, 1.2% (4/327) of the subjects discontinued treatment due to local skin/application site reactions.

The incidence and severity of local skin reactions during controlled clinical trials are shown in Table 9.

Table 9: Local Skin Reactions in the Treatment Area of Imiquimod-Treated Subjects with EGW as Assessed by the Investigator in Vehicle-Controlled Clinical Trials

	Imiquimod Cream				Vehicle			
	Females (n=114)		Males (n=156)		Females (n=99)		Males (n=157)	
	All Grades*	Severe	All Grades*	Severe	All Grades*	Severe	All Grades*	Severe
Erythema	74 (65%)	4 (4%)	90 (58%)	6 (4%)	21 (21%)	0 (0%)	34 (22%)	0 (0%)
Erosion	35 (31%)	1 (1%)	47 (30%)	2 (1%)	8 (8%)	0 (0%)	10 (6%)	0 (0%)
Excoriation/ Flaking	21 (18%)	0 (0%)	40 (26%)	1 (1%)	8 (8%)	0 (0%)	12 (8%)	0 (0%)
Edema	20 (18%)	1 (1%)	19 (12%)	0 (0%)	5 (5%)	0 (0%)	1 (1%)	0 (0%)
Scabbing	4 (4%)	0 (0%)	20 (13%)	0 (0%)	0 (0%)	0 (0%)	4 (3%)	0 (0%)
Induration	6 (5%)	0 (0%)	11 (7%)	0 (0%)	2 (2%)	0 (0%)	3 (2%)	0 (0%)
Ulceration	9 (8%)	3 (3%)	7 (4%)	0 (0%)	1 (1%)	0 (0%)	1 (1%)	0 (0%)
Vesicles	3 (3%)	0 (0%)	3 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)

*Mild, Moderate, or Severe

Remote site skin reactions were also reported. The severe remote site skin reactions reported for females were erythema (3%), ulceration (2%), and edema (1%); and for males, erosion (2%), and erythema, edema, induration, and excoriation/flaking (each 1%).

Other adverse reactions reported by more than 1% of imiquimod-treated subjects included:

Application Site Disorders: hypopigmentation, irritation, rash, sensitivity, stinging, tenderness

Body as a Whole: fatigue, fever

Gastrointestinal System Disorders: diarrhea

Remote Site Reactions: bleeding, burning, itching, pain, tenderness, tinea cruris

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of imiquimod cream. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Application Site Disorders: tingling at the application site

Body as a Whole: angioedema

Cardiovascular: capillary leak syndrome, cardiac failure, cardiomyopathy, pulmonary

edema, arrhythmias (tachycardia, atrial fibrillation, palpitations), chest pain, ischemia, myocardial infarction, syncope

Endocrine: thyroiditis

Gastrointestinal System Disorders: abdominal pain

Hematological: decreases in red cell, white cell, and platelet counts (including idiopathic thrombocytopenic purpura), lymphoma

Hepatic: abnormal liver function

Infections and Infestations: herpes simplex

Musculoskeletal System Disorders: arthralgia

Neuropsychiatric: agitation, cerebrovascular accident, convulsions (including febrile convulsions), depression, insomnia, multiple sclerosis aggravation, paresis, suicide

Respiratory: dyspnea

Urinary System Disorders: proteinuria, dysuria, urinary retention

Skin and Appendages: exfoliative dermatitis, erythema multiforme, hypertrophic scar, hyperpigmentation, hypopigmentation, including complete depigmentation.

Vascular: Henoch-Schönlein purpura syndrome

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

Available data from case reports and case series of use with imiquimod during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. There are no controlled or large-scale epidemiologic studies and no exposure registries with imiquimod use in pregnant women.

In animal reproduction studies, there were no adverse developmental effects observed after oral administration of imiquimod in pregnant rats and intravenous administration of imiquimod in pregnant rabbits during organogenesis at doses up to 98 times and 407 times, respectively, the maximum recommended human dose (MRHD) (*see Data*).

The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.

Data

Animal Data

The MRHD was set at 2 packets per treatment of Imiquimod Cream (25 mg imiquimod) for the animal multiples of human exposure presented in this label.

Systemic embryofetal development studies were conducted in rats and rabbits. Oral doses of 1, 5, and 20 mg/kg/day imiquimod were administered during the period of organogenesis to pregnant female rats. In the presence of maternal toxicity, fetal effects noted at 20 mg/kg/day (577 times the MRHD based on AUC comparison) included increased resorptions, decreased fetal body weights, delays in skeletal ossification, bent limb bones, and two fetuses in one litter (2 of 1567 fetuses) demonstrated exencephaly, protruding tongues and low-set ears. No treatment-related effects on embryofetal toxicity or malformation were noted at 5 mg/kg/day (98 times the MRHD based on AUC comparison).

Intravenous doses of 0.5, 1, and 2 mg/kg/day imiquimod were administered during the period of organogenesis to pregnant female rabbits. No treatment-related effects on embryofetal toxicity or malformation were noted at 2 mg/kg/day (1.5 times the MRHD based on BSA comparison), the highest dose evaluated in this study, or 1 mg/kg/day (407 times the MRHD based on AUC comparison).

A combined fertility and peri- and postnatal development study was conducted in rats. Oral doses of 1, 1.5, 3, and 6 mg/kg/day imiquimod were administered to male rats from 70 days prior to mating through the mating period and to female rats from 14 days prior to mating through parturition and lactation. No effects on growth, fertility, reproduction, or postnatal development were noted at doses up to 6 mg/kg/day (87 times the MRHD based on AUC comparison), the highest dose evaluated in this study. In the absence of maternal toxicity, bent limb bones were noted in the F1 fetuses at a dose of 6 mg/kg/day (87 times the MRHD based on AUC comparison). This fetal effect was also noted in the oral rat embryofetal development study conducted with imiquimod. No treatment-related malformations were noted at 3 mg/kg/day (41 times the MRHD based on AUC comparison).

8.2 Lactation

Risk Summary

There is no information available on the presence of imiquimod in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production after topical application of Imiquimod Cream to women who are breastfeeding. Systemic concentration following topical administration of imiquimod cream is low; therefore, transfer of Imiquimod Cream into breastmilk is likely to be low [see *Clinical Pharmacology* (12.3)]. The development and health benefits of breastfeeding should be considered along with the mother's clinical need for Imiquimod Cream and any potential adverse effects on the breastfed infant from Imiquimod Cream or from the underlying maternal condition.

Clinical Considerations

Avoid application of Imiquimod Cream to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child.

8.4 Pediatric Use

Actinic Keratosis and Superficial Basal Cell Carcinoma

The safety and effectiveness of Imiquimod Cream for the treatment of AK or sBCC in pediatric patients have not been established.

External Genital Warts

The safety and effectiveness of Imiquimod Cream for the treatment of EGW in pediatric patients 12 years of age and older have been established. Use of Imiquimod Cream for this indication is supported by evidence from adequate and well controlled trials in adults [see *Clinical Studies* (14.3)]. The safety and effectiveness of Imiquimod Cream for the treatment of EGW in pediatric patients less than 12 years of age have not been established.

Molluscum Contagiosum

The safety and effectiveness of Imiquimod Cream for the treatment of molluscum contagiosum (MC) in pediatric patients have not been established. Safety and effectiveness of Imiquimod Cream was not demonstrated in two randomized, vehicle-controlled, double-blind trials involving 702 pediatric subjects with MC (470 exposed to Imiquimod Cream; median age 5 years, range 2–12 years).

Adverse reactions reported in pediatric subject with MC (and not previously reported) included otitis media (5% Imiquimod Cream vs. 3% vehicle) and conjunctivitis (3% Imiquimod Cream vs. 2% vehicle).

In a pharmacokinetics trial in subjects aged 2 to 12 years with extensive MC involving at least 10% of total body surface area; among the 20 subjects with evaluable laboratory assessments, the median white blood cell (WBC) count decreased by $1.4 \times 10^9/L$ and the median absolute neutrophil count decreased by $1.42 \times 10^9/L$.

8.5 Geriatric Use

Of the 215 subjects treated with imiquimod cream in the AK clinical trials, 127 subjects (59%) were 65 years of age or older, while 60 subjects (28%) were 75 years of age or older. Of the 185 subjects treated with imiquimod cream in the sBCC clinical trials, 65 subjects (35%) were 65 years of age or older, while 25 subjects (14%) were 75 years of age or older. No overall differences in safety or effectiveness of Imiquimod Cream have been observed between subjects 65 years of age and older and younger adult subjects.

10 OVERDOSAGE


Topical overdosing of Imiquimod Cream could result in an increased incidence of severe local skin reactions and may increase the risk for systemic reactions.

The most clinically serious adverse reaction reported following multiple oral imiquimod doses of >200 mg (equivalent to imiquimod content of >16 packets of Imiquimod Cream) was hypotension, which resolved following oral or intravenous fluid administration. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.

11 DESCRIPTION

Imiquimod Cream, 5% is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of benzyl alcohol, cetyl alcohol, glycerin, methylparaben, oleic acid, oleyl alcohol, polysorbate 60, propylparaben, purified water, stearyl alcohol, sorbitan monostearate, white petrolatum, and xanthan gum.

Chemically, imiquimod is 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinolin-4-amine. Imiquimod has a molecular formula of C₁₄H₁₆N₄ and a molecular weight of 240.3. Its structural formula is:



12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

The mechanism of action of Imiquimod Cream in treating AK, sBCC, and EGW lesions is unknown.

12.2 Pharmacodynamics

Actinic Keratosis

In a trial of 18 subjects with AK comparing imiquimod cream to vehicle, increases from baseline in Week 2 biomarker levels were reported for CD3, CD4, CD8, CD11c, and CD68 for imiquimod-treated subjects; however, the clinical relevance of these findings is unknown.

Superficial Basal Cell Carcinoma

An open-label trial in 6 subjects with sBCC suggests that treatment with imiquimod cream may increase the infiltration of lymphocytes, dendritic cells, and macrophages into the tumor lesion; however, the clinical significance of these findings is unknown.

External Genital Warts

Imiquimod has no direct antiviral activity in cell culture. A trial in 22 subjects with EGW comparing imiquimod cream and vehicle shows that imiquimod cream induces mRNA encoding cytokines including interferon- α at the treatment site. In addition, HPVL1 mRNA and HPV DNA are significantly decreased following treatment. However, the clinical relevance of these findings is unknown.

12.3 Pharmacokinetics

Absorption

Systemic absorption of imiquimod across the affected skin of 58 subjects with AK was observed with a dosing frequency of 3 applications per week for 16 weeks. Mean peak serum drug concentrations at the end of Week 16 were approximately 0.1, 0.2, and 3.5 ng/mL for the applications to face (12.5 mg imiquimod, 1 unit-dose packet), scalp (25

mg, 2 packets), and hands/arms (75 mg, 6 packets), respectively.

Table 10: Mean Serum Imiquimod Concentration in Adults Following Administration of the Last Topical Dose during Week 16 (Actinic Keratosis)

Amount of Imiquimod Cream Applied	Mean Peak Serum Imiquimod Concentration [C_{max}]
12.5 mg (1 packet)	0.1 ng/mL
25 mg (2 packets)	0.2 ng/mL
75 mg (6 packets)	3.5 ng/mL

The application surface area was not controlled when more than 1 packet was used. Dose proportionality was not observed. However, it appears that systemic exposure may be more dependent on surface area of application than amount of applied dose. The apparent half-life was approximately 10 times greater with topical dosing than the 2-hour apparent half-life seen following subcutaneous dosing, suggesting prolonged retention of drug in the skin. Mean urinary recoveries of imiquimod and metabolites combined were 0.08% and 0.15% of the applied dose in the group using 75 mg (6 packets) for males and females, respectively following 3 applications per week for 16 weeks.

Systemic absorption of imiquimod was observed across the affected skin of 12 subjects with genital/perianal warts, with an average dose of 4.6 mg. Mean peak drug concentration of approximately 0.4 ng/mL was seen during the trial. Mean urinary recoveries of imiquimod and metabolites combined over the whole course of treatment, expressed as percent of the estimated applied dose, were 0.11% and 2.41% in the males and females, respectively.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

In an oral (gavage) rat carcinogenicity study, imiquimod was administered to Wistar rats on a 2 times per week (up to 6 mg/kg/day) or daily (3 mg/kg/day) dosing schedule for 24 months. No treatment-related tumors were noted in the oral rat carcinogenicity study up to the highest doses tested in this study of 6 mg/kg administered 2 times per week in female rats (87 times the MRHD based on weekly AUC comparison), 4 mg/kg administered 2 times per week in male rats (75 times the MRHD based on weekly AUC comparison), or 3 mg/kg administered 7 times per week to male and female rats (153 times the MRHD based on weekly AUC comparison).

In a dermal mouse carcinogenicity study, imiquimod cream (up to 5 mg/kg/application imiquimod or 0.3% imiquimod cream) was applied to the backs of mice 3 times per week for 24 months. A statistically significant increase in the incidence of liver adenomas and carcinomas was noted in high dose male mice compared to control male mice (251 times the MRHD based on weekly AUC comparison). An increased number of skin papillomas was observed in vehicle cream control group animals at the treated site only.

Imiquimod revealed no evidence of mutagenic or clastogenic potential based on the results of five *in vitro* genotoxicity tests (Ames assay, mouse lymphoma L5178Y assay,

Chinese hamster ovary cell chromosome aberration assay, human lymphocyte chromosome aberration assay, and SHE cell transformation assay) and three *in vivo* genotoxicity tests (rat and hamster bone marrow cytogenetics assay and a mouse-dominant lethal test). Daily oral administration of imiquimod to rats, throughout mating, gestation, parturition, and lactation, demonstrated no effects on growth, fertility or reproduction, at doses up to 87 times the MRHD based on AUC comparison.

14 CLINICAL STUDIES

14.1 Actinic Keratosis

In two double-blind, vehicle-controlled clinical trials, 436 subjects with AK were randomized to treatment with either imiquimod cream, 5% or vehicle applied topically once daily 2 times per week for 16 weeks (Studies AK1 and AK2). The trials enrolled subjects with 4 to 8 clinically typical, visible, discrete, nonhyperkeratotic, nonhypertrophic AK lesions within a 25 cm² contiguous treatment area on either the face or scalp. The 25 cm² contiguous treatment area could be of any dimensions (e.g., 5 cm × 5 cm, 3 cm × 8.3 cm, 2 cm × 12.5 cm). Trial subjects ranged from 37 to 88 years of age (median 66 years) and 55% had Fitzpatrick skin type I or II. All imiquimod-treated subjects were White.

On a scheduled dosing day, the trial cream was applied to the entire treatment area prior to normal sleeping hours and left on for approximately 8 hours. Twice-weekly dosing was continued for a total of 16 weeks. The clinical response of each subject was evaluated 8 weeks after the last scheduled application of trial cream. Efficacy was assessed by the complete clearance rate, defined as the proportion of subjects at the 8-week post-treatment visit with no (zero) clinically visible AK lesions in the treatment area. Complete clearance included clearance of all baseline lesions, as well as any new or subclinical AK lesions which appeared during therapy.

Complete and partial clearance rates are shown in Table 11. The partial clearance rate was defined as the percentage of subjects in whom 75% or more baseline AK lesions were cleared.

Table 11: Clearance Rates of AK at 8 Weeks Post-Treatment

Complete Clearance Rates (100% AK Lesions Cleared)		
Trial	Imiquimod Cream	Vehicle
Study AK1	46% (49/107)	3% (3/110)
Study AK2	44% (48/108)	4% (4/111)
Partial and Complete Clearance Rates (75% or More Baseline AK Lesions Cleared)		
Trial	Imiquimod Cream	Vehicle
Study AK1	60% (64/107)	10% (11/110)
Study AK2	58% (63/108)	14% (15/111)

During treatment, 48% (103/215) of imiquimod-treated subjects experienced an increase in AK lesions relative to the number present at baseline within the treatment area. Subjects with an increase in AK lesions had a similar response to those with no

increase in AK lesions.

14.2 Superficial Basal Cell Carcinoma

In two double-blind, vehicle-controlled clinical trials, 364 subjects with primary sBCC were treated with imiquimod cream, 5% or vehicle applied topically once daily 5 times per week for 6 weeks (Studies sBCC1 and sBCC2). Target tumors were biopsy-confirmed sBCC and had a minimum area of 0.5 cm² and a maximum diameter of 2.0 cm (4.0 cm²). Target tumors were not to be located within 1.0 cm of the hairline, or on the anogenital area or on the hands or feet, or to have any atypical features. The population ranged from 31 to 89 years of age (median 60 years) and 65% had Fitzpatrick skin type I or II. On a scheduled dosing day, trial cream was applied to the target tumor and approximately 1 cm (about 1/3 inch) beyond the target tumor prior to normal sleeping hours, and 5 times per week dosing was continued for a total of 6 weeks. The target tumor area was clinically assessed 12 weeks after the last scheduled application of trial cream. The entire target tumor was then excised and examined histologically for the presence of tumor.

Efficacy was assessed by the complete response rate defined as the proportion of subjects with clinical (visual) and histological clearance of the sBCC lesion at 12 weeks post-treatment. Of imiquimod-treated subjects, 6% (11/178) who had both clinical and histological assessments post-treatment, and who appeared to be clinically clear had evidence of tumor on excision of the clinically clear treatment area.

Data on composite clearance (defined as both clinical and histological clearance) are shown in Table 12.

Table 12: Composite Clearance Rates at 12 Weeks Post-Treatment for sBCC

Trial	Imiquimod Cream	Vehicle
Study sBCC1	70% (66/94)	2% (2/89)
Study sBCC2	80% (73/91)	1% (1/90)
Total	75% (139/185)	2% (3/179)

A separate 5-year, open-label trial was conducted to assess the recurrence of sBCC treated with imiquimod cream applied topically once daily 5 days per week for 6 weeks. Target tumor inclusion criteria were the same as for the trials described above. At 12 weeks post-treatment, subjects were clinically evaluated for evidence of persistent sBCC (no histological assessment). Subjects with no clinical evidence of sBCC entered the long-term follow-up period. At the 12-week post-treatment assessment, 90% (163/182) of the subjects enrolled had no clinical evidence of sBCC at their target site and 162 subjects entered the long-term follow-up period for up to 5 years. Two-year (24-month) follow-up data are available from this trial and are presented in Table 13.

Table 13: Estimated Clinical Clearance Rates for sBCC in Imiquimod-Treated Subjects During Follow-up Period in Open-Label Trial

Follow-up Visit after 12-Week Post-	No. of Subjects Who Remained	No. of Subjects with sBCC	No. of Subjects Who Discontinued at	Estimated Rate of Subjects Who Clinically Cleared
--	-------------------------------------	----------------------------------	--	--

Treatment Assessment	Clinically Clear	Recurrence	This Visit with No sBCC^a	and Remained Clear^b
Month 3	153	4	5	87%
Month 6	149	4	0	85%
Month 12	143	2	4	84%
Month 24	139	4	0	79%


^a Reasons for discontinuation included death, noncompliance, entry criteria violations, personal reasons, and treatment of nearby sBCC tumor.

^b Estimated rate of subjects who clinically cleared and remained clear are estimated based on the time to event analysis employing the life table method beginning with the rate of clinical clearance at 12 weeks post-treatment.

14.3 External Genital Warts

In a double-blind, placebo-controlled clinical trial, 209 otherwise healthy subjects 18 years and older with EGW were treated with imiquimod cream, 5% or vehicle applied topically once daily 3 times per week for a maximum of 16 weeks (Study EGW1). The median baseline wart area was 69 mm² (range 8 to 5525 mm²). Subject accountability is shown in the figure below.

Figure 1: Subject Accountability for Study EGW1



* The other subjects were either lost to follow-up or experienced recurrences.

Data on complete clearance are listed in Table 14. The median time to complete wart clearance was 10 weeks.

Table 14: Complete Clearance Rates of EGW in Study EGW1

Treatment	Subjects with Complete Clearance of Warts	Subjects Without Follow-up	Subjects with Warts Remaining at Week 16
Overall			
Imiquimod Cream (n =109)	54 (50%)	19 (17%)	36 (33%)
Vehicle (n =100)	11 (11%)	27 (27%)	62 (62%)
Females			

Imiquimod Cream (n =46)	33 (72%)	5 (11%)	8 (17%)
Vehicle (n =40)	8 (20%)	13 (33%)	19 (48%)
Males			
Imiquimod Cream (n =63)	21 (33%)	14 (22%)	28 (44%)
Vehicle (n =60)	3 (5%)	14 (23%)	43 (72%)

16 HOW SUPPLIED/STORAGE AND HANDLING

Imiquimod Cream, 5% is supplied in unit-dose packets each of which contains 250 mg of a white to off-white cream.

Available as: a box of 12 packets (NDC 45802-**368**-53) and a box of 24 packets (NDC 45802-**368**-62).

Store at 4°-25°C (39°-77°F). Avoid freezing.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Important Administration Instructions

Inform all patients of the following: *[see Dosage and Administration (2.1)]*

- Imiquimod Cream is for topical use only; avoid contact with the eyes, lips, nostrils, or inside the anus and vagina.
Instruct patients to rinse their mouth or eyes with water right away if contact with these areas occur.
- Wash hands before and after applying Imiquimod Cream.
- If an Imiquimod Cream dose is missed, apply the next dose at the regularly scheduled time.
- Discard and do not reuse partially used packets.

Inform patients with EGW of the following *[see Dosage and Administration (2.4)]*:

- Uncircumcised patients treating warts under the foreskin should retract the foreskin and clean the area daily.
- Imiquimod Cream may weaken condoms and vaginal diaphragms; therefore, concurrent use is not recommended.
- Avoid sexual (genital, anal, oral) contact while Imiquimod Cream is on the skin.
- Do not bandage or otherwise occlude the treatment area.

Lactation

Advise breastfeeding women to avoid application of Imiquimod Cream to areas with increased risk for potential ingestion by or ocular exposure to the breastfeeding child *[see Use in Specific Populations (8.2)]*.

Local Skin Reactions

Inform patients of the following *[see Dosage and Administration (2.2, 2.3, 2.4) and Warnings and Precautions (5.1)]*:

- Local skin reactions may occur during treatment with Imiquimod Cream, ranging from mild to severe in intensity and extending beyond the application site onto the surrounding skin, and may require an interruption of dosing.
- For female patients being treated for EGW, apply Imiquimod Cream at the opening of the vagina, avoiding intravaginal application because local skin reactions may cause difficulty in passing urine.
- If severe local skin reactions occur, remove Imiquimod Cream by washing the treatment area with mild soap and water.
- Contact their healthcare provider promptly if they experience any sign or symptom at the application site that restricts or prohibits their daily activity or makes continued application of Imiquimod Cream difficult.
- Because of local skin reactions, during treatment and until healed, the treatment area is likely to appear noticeably different from normal skin.

Local Hypopigmentation Reactions

Inform patients that cases of hypopigmentation, including complete depigmentation, were reported during postmarketing use of Imiquimod Cream and, in some cases, hypopigmentation and complete depigmentation did not improve or resolve with treatment and persisted for up to 60 months at the time of reporting. Advise patient to inform their healthcare provider if hypopigmentation is observed *[see Warnings and Precautions (5.2)]*.

Systemic Reactions

Inform patients that they may experience flu-like systemic signs and symptoms during treatment with Imiquimod Cream and these symptoms may require an interruption of dosing *[see Warnings and Precautions (5.3)]*.

Ultraviolet Light Exposure Risks

Instruct patients to avoid or minimize exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) while using Imiquimod Cream. Instruct patients to use sunscreen and to wear protective clothing, and to not use Imiquimod Cream if sunburned *[see Warnings and Precautions (5.4)]*.

Manufactured by Padagis®
Yeruham, Israel
www.padagis.com

Rev 01-25
2H100 RC PH8

Patient Information

Patient Information Imiquimod (i-mi-KWI-mod) Cream, 5%
Important: For use on the skin only (topical). Do not use Imiquimod Cream in your mouth, eyes or vagina.
What is Imiquimod Cream? Imiquimod Cream is a prescription medicine used on the skin (topical) to treat: • actinic keratosis on the face or scalp in adults with normal immune systems.

- a type of skin cancer called superficial basal cell carcinoma in adults with normal immune systems when surgery is not an option.
- warts on the outside of the genitals (external) and around the outside of the anus (perianal) in people 12 years and older.

It is not known if Imiquimod Cream is safe and effective in the treatment of:

- people who have weakened immune system.
- people with basal cell nevus syndrome or extreme sensitivity to sunlight (xeroderma pigmentosum).

It is not known if Imiquimod Cream is safe and effective for the treatment of actinic keratosis or superficial basal cell carcinoma in children less than 18 years of age.

It is not known if Imiquimod Cream is safe and effective for the treatment of external genital and perianal warts in children below the age of 12.

Before using Imiquimod Cream, tell your healthcare provider about all of your medical conditions, including if you:

- have problems with your immune system, including long-lasting (chronic) graft versus host disease.
- are being treated or have been treated with other medicines or surgery. You should not use Imiquimod Cream until your skin has healed from other treatments.
- have other skin problems or sunburn.
- are pregnant or plan to become pregnant. It is not known if Imiquimod Cream can harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if imiquimod passes into your breast milk. If you breastfeed during treatment with Imiquimod Cream, avoid contact of your treated skin with your baby's mouth or eyes. Talk to your healthcare provider about the best way to feed your baby if you use Imiquimod Cream.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.

How should I use Imiquimod Cream?

- Use Imiquimod Cream exactly as prescribed by your healthcare provider.
- Your healthcare provider should show you how to apply Imiquimod Cream.
- Apply Imiquimod Cream just before your bedtime.
- Do not use more Imiquimod Cream than you need to cover the affected area. Using too much Imiquimod Cream, or using it too often, or for too long can increase your chances for having a severe skin reaction or other side effect.
- After applying Imiquimod Cream, the opened packet should be thrown away even if all the Imiquimod Cream was not used.

When using Imiquimod Cream for actinic keratosis:

- Apply Imiquimod Cream 2 times per week for 16 weeks. Examples of 2 times per week application schedules are Monday and Thursday, **or** Tuesday and Friday.
- Imiquimod Cream should be left on the treated area for about 8 hours. After this time, wash the treated area with mild soap and water to remove Imiquimod Cream.

When using Imiquimod Cream for superficial basal cell carcinoma:

- Apply Imiquimod Cream 1 time a day, for 5 days a week, for example Monday through Friday. Treatment with Imiquimod Cream should continue for 6 full weeks, even if the superficial basal cell carcinoma appears to be gone.
- Apply Imiquimod Cream to the superficial basal cell carcinoma and to 1 centimeter (cm) of skin surrounding the treatment area.
- Imiquimod Cream should be left on the treated area for about 8 hours. After this time, wash the treated area with mild soap and water to remove Imiquimod Cream.

When using Imiquimod Cream for external or perianal warts:

- Apply Imiquimod Cream 3 times per week. Examples of 3 times per week application schedules are Monday, Wednesday and Friday, **or** Tuesday, Thursday, and Saturday.
- Treatment with Imiquimod Cream should continue until there is complete clearance of all warts or up to 16 weeks. Imiquimod Cream will not cure your genital or perianal warts. New warts may develop during treatment with Imiquimod Cream.
- Uncircumcised males treating warts under their penis foreskin must pull their foreskin back and clean before treatment, and clean daily during the prescribed weeks of treatment.
- Do not get Imiquimod Cream in the anus when applying to perianal warts.
- Imiquimod Cream should be left on the treated area for 6 to 10 hours. After this time, wash the treated area with mild soap and water.

Applying Imiquimod Cream:

- Wash the area where Imiquimod Cream will be applied with mild soap and water.
- Allow the area to dry for at least 10 minutes.
- Wash your hands well.
- Open a new packet of Imiquimod Cream just before use.
- Apply a thin layer of Imiquimod Cream **only** to the affected area(s) to be treated.
- Rub Imiquimod Cream in all the way until you cannot see the cream on the affected area(s).
- Wash your hands well after applying Imiquimod Cream.
- After about 8 hours, wash the treated area(s) with mild soap and water. Do not leave Imiquimod Cream on your skin longer than prescribed.
- If you forget to apply Imiquimod Cream, apply the next dose of Imiquimod Cream at your regularly scheduled time.
- If you get Imiquimod Cream in your mouth or in your eyes, rinse well with water right away.

What should I avoid while using Imiquimod Cream?

- **Do not** cover the treated site with bandages or other closed dressings. Cotton gauze dressings can be used if needed. Cotton underwear can be worn after treating the genital or perianal area.
- **Do not** use sunlamps or tanning beds, and avoid sunlight as much as possible during treatment with Imiquimod Cream. Use sunscreen and wear protective clothing if you go outside during daylight.
- **Do not** have sexual contact including genital, anal, or oral sex when Imiquimod Cream is on your genitals or perianal skin. Imiquimod Cream may weaken condoms and vaginal diaphragms. This means they may not work as well to prevent pregnancy.

What are the possible side effects of Imiquimod Cream?

- **Treatment site skin reactions.** Skin reactions including drainage (weeping) or breakdown of the outer layer of your skin (erosion) can happen after a few applications of Imiquimod Cream. Swelling outside of the vagina (vulvar swelling) may happen in females. Females should take special care if applying the cream at the opening of the vagina because skin reactions can cause pain or swelling and may cause problems passing urine. If you get skin reactions, wash the treated area with mild soap and water. **Stop Imiquimod Cream right away and call your healthcare provider if you get any skin reactions that affect your daily activities, or that do not go away.**

- **Flu-like symptoms.** Tell your healthcare provider if you get tiredness, fever, nausea, muscle pain, joint pain, and chills.

Your healthcare provider may temporarily stop or completely stop your treatment with Imiquimod Cream if you develop treatment site skin reactions or flu-like symptoms.

If you are using Imiquimod Cream for the treatment of superficial basal cell

carcinoma, it is very important to have regular follow-up visits with your healthcare provider to check the area to make sure your skin cancer has not come back.

The most common side effects of Imiquimod Cream are skin reactions at the treatment site including:

- redness
- swelling
- a sore, blister, or ulcer
- burning
- skin that becomes hard or thickened
- changes in skin color that do not always
- itching
- scabbing and crusting
- flaking
- scaling
- dryness

go away

- skin peeling

Other side effect of Imiquimod Cream include: headache.

These are not all of the possible side effects of Imiquimod Cream.

Call your doctor for medical advice about side effects.

You may report side effects to FDA at 1-800-FDA-1088.

How do I store Imiquimod Cream?

- Store Imiquimod Cream at 39°F to 77°F (4°C to 25°C).
- Do not freeze.
- Safely throw away Imiquimod Cream that is out of date, unused or partially used.

Keep Imiquimod Cream and all medicines out of reach of children.

General information about the safe and effective use of Imiquimod Cream.

Medicines are sometimes prescribed for purposes other than those in a Patient Information leaflet. Do not use Imiquimod Cream for a condition for which it was not prescribed. Do not give Imiquimod Cream to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Imiquimod Cream that is written for the health professionals.

What are the ingredients in Imiquimod Cream?

Active Ingredient: imiquimod

Inactive ingredients: benzyl alcohol, cetyl alcohol, glycerin, methylparaben, oleic acid, oleyl alcohol, polysorbate 60, propylparaben, purified water, stearyl alcohol, sorbitan monostearate, white petrolatum, and xanthan gum.

Manufactured by Padagis®

Yeruham, Israel

www.padagis.com

Rev 01-25 2H100 RC PH8

This Patient Information has been approved by the U.S. Food and Drug Administration.

PRINCIPAL DISPLAY PANEL


NDC 45802-368-53

Rx Only

Imiquimod Cream, 5%

For Dermatologic Use Only.

NET WT per Carton 3g



Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:45802-368
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
IMIQUIMOD (UNII: P1QW714R7M) (IMIQUIMOD - UNII:P1QW714R7M)	IMIQUIMOD	12.5 mg in 0.25 g

Inactive Ingredients	
Ingredient Name	Strength
BENZYL ALCOHOL (UNII: LKG8494WBH)	
CETYL ALCOHOL (UNII: 936JST6JCN)	
GLYCERIN (UNII: PDC6A3C0OX)	
METHYLPARABEN (UNII: A2I8C7HI9T)	
OLEIC ACID (UNII: 2UMI9U37CP)	
OLEYL ALCOHOL (UNII: 172F2WN8DV)	
POLYSORBATE 60 (UNII: CAL22UVI4M)	
PROPYLPARABEN (UNII: Z8IX2SC1OH)	
WATER (UNII: 059QF0KO0R)	
STEARYL ALCOHOL (UNII: 2KR89I4H1Y)	
SORBITAN MONOSTEARATE (UNII: NVZ4I0H58X)	
PETROLATUM (UNII: 4T6H12BN9U)	
XANTHAN GUM (UNII: TTV12P4NEE)	

Product Characteristics			
Color	WHITE (OFF)	Score	
Shape		Size	
Flavor		Imprint Code	
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:45802-368-53	12 in 1 CARTON	07/12/2012	
1		0.25 g in 1 PACKET; Type 0: Not a Combination Product		
2	NDC:45802-368-62	24 in 1 CARTON	11/09/2010	
2		0.25 g in 1 PACKET; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA078837	11/09/2010	

Labeler - Padagis Israel Pharmaceuticals Ltd (600093611)

Revised: 1/2025

Padagis Israel Pharmaceuticals Ltd